{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT06346509",
            "orgStudyIdInfo": {
                "id": "PORT-77-101"
            },
            "organization": {
                "fullName": "Portal Therapeutics, Inc.",
                "class": "INDUSTRY"
            },
            "briefTitle": "Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Study of PORT-77 Administered to Healthy Adult Participants",
            "officialTitle": "A Phase 1, First-in-Human, Randomized, Double-Blind, Placebo-Controlled, Single and Multiple Ascending Dose and Food Effect Study of PORT-77 Administered Orally to Healthy Adult Participants",
            "therapeuticArea": [
                "Other"
            ],
            "study": "randomized-double-blind-placebo-controlled-single-and-multiple-ascending-dose-study-of-port-administered-to-healthy-adult-participants"
        },
        "statusModule": {
            "statusVerifiedDate": "2024-03",
            "overallStatus": "NOT_YET_RECRUITING",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2024-04-08",
                "type": "ESTIMATED"
            },
            "primaryCompletionDateStruct": {
                "date": "2024-12-23",
                "type": "ESTIMATED"
            },
            "completionDateStruct": {
                "date": "2024-12-23",
                "type": "ESTIMATED"
            },
            "studyFirstSubmitDate": "2024-03-21",
            "studyFirstSubmitQcDate": "2024-03-28",
            "studyFirstPostDateStruct": {
                "date": "2024-04-04",
                "type": "ACTUAL"
            },
            "lastUpdateSubmitDate": "2024-03-28",
            "lastUpdatePostDateStruct": {
                "date": "2024-04-04",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Portal Therapeutics, Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true,
            "isFdaRegulatedDrug": true,
            "isFdaRegulatedDevice": false
        },
        "descriptionModule": {
            "briefSummary": "A First-in-Human 2-part, randomized, double-blind, placebo-controlled, single ascending dose, multiple ascending dose, and food effect, investigation of the administration of PORT-77 in healthy adult participants."
        },
        "conditionsModule": {
            "conditions": [
                "Healthy Adult Participants"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE1"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "SEQUENTIAL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 108,
                "type": "ESTIMATED"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "PORT-77",
                    "type": "EXPERIMENTAL",
                    "description": "Healthy adult participants in each cohort will receive a single oral dose of PORT 77 or matching placebo on Day 1.",
                    "interventionNames": [
                        "Drug: PORT-77"
                    ]
                },
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "description": "Healthy adult participants in each cohort will receive a single oral dose of PORT 77 or matching placebo on Day 1.",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "PORT-77",
                    "description": "Healthy adult participants will receive a single oral dose of PORT 77.",
                    "armGroupLabels": [
                        "PORT-77"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Healthy adult participants will receive matching placebo on Day 1.",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Number of incidence and severity of adverse events (AEs) as a measure of safety and tolerability of PORT-77 (Part I)",
                    "timeFrame": "Day 8"
                },
                {
                    "measure": "Number of incidence and severity of AEs as a measure of safety and tolerability of PORT-77 (Part II)",
                    "timeFrame": "Day 21"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Plasma concentration of a single-dose of PORT-77 (Part I)",
                    "timeFrame": "Day 8"
                },
                {
                    "measure": "Plasma concentration of the steady-state of PORT-77 (Part II)",
                    "timeFrame": "Day 21"
                },
                {
                    "measure": "Plasma concentration of PORT-77 by effect of a standardized high-fat/high-calorie meal (Part I)",
                    "timeFrame": "Day 4"
                },
                {
                    "measure": "Evaluate effects of single doses of PORT-77 on ECG parameters (Part I)",
                    "timeFrame": "Day 8"
                },
                {
                    "measure": "Evaluate effects of single doses of PORT-77 on ECG parameters (Part II)",
                    "timeFrame": "Day 21"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* All healthy adult participants must be willing and able to follow protocol-specified assessments.\n* Healthy based on no clinically significant medical history, physical examination, laboratory profiles, vital signs, and Electrocardiograms (ECGs), as deemed by the Principal Investigator (PI) or designee.\n\nExclusion Criteria:-\n\n* Is mentally or legally incapacitated or has significant emotional problems at the time of the screening visit or expected during the conduct of the study.\n* History or presence of clinically significant medical or psychiatric condition or disease in the opinion of the PI or designee.\n* Female subject with a positive pregnancy test at the screening visit or at first check-in or who is lactating.\n* Participation in another clinical study within 60 days or within 10 half-lives (if known), prior to the first dosing, whichever is longer, or previous participation in another PORT 77 study or study part.",
            "healthyVolunteers": true,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "maximumAge": "55 Years",
            "stdAges": [
                "ADULT"
            ]
        },
        "contactsLocationsModule": {
            "centralContacts": [
                {
                    "name": "Portal Therapeutics, SVP Clinical Development",
                    "role": "CONTACT",
                    "phone": "650-391-9740",
                    "email": "Portal.clinical.trials@bridgebio.com"
                }
            ],
            "overallOfficials": [
                {
                    "name": "Portal Therapeutics, VP Clinical Development",
                    "affiliation": "Portal Therapeutics",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Celerion",
                    "city": "Tempe",
                    "state": "Arizona",
                    "zip": "85283",
                    "country": "United States",
                    "contacts": [
                        {
                            "role": "CONTACT",
                            "email": "mara.baier@celerion.com"
                        },
                        {
                            "name": "Mara Baier, DO",
                            "role": "PRINCIPAL_INVESTIGATOR"
                        }
                    ],
                    "geoPoint": {
                        "lat": 33.41477,
                        "lon": -111.90931
                    }
                }
            ]
        },
        "ipdSharingStatementModule": {
            "ipdSharing": "NO"
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2024-07-30"
        }
    },
    "hasResults": false
}